Navigation Links
ArrayScript RT: Maximize Yields of Full-length cDNA

al RNA, ArrayScript often eliminates the need for two rounds of amplification, still generating sufficient cRNA for array analysis. This translates to significant savings of time and reagents.

Figure 2. ArrayScript Reverse Transcriptase Produces up to Twice the cRNA Yield in MessageAmp II. A comparison of ArrayScript RT (AS; 200 U), SuperScript II (SSII; 200 U); wild type M-MLV RT (200 U), and wild type AMV RT (10 U) in MessageAmp II conditions demonstrates that ArrayScript outperforms other commercial RTs. 90 ng HeLa-S3 total RNA (28S/18S ratio = 1.7) was heat denatured in the presence of T7 Oligo(dT) at 70C for 10 minutes. Reverse transcription was initiated with the RT enzyme and incubated at 42C for 2 hr in an air incubator. Following first-strand cDNA synthesis, DNA polymerase was added for second-strand synthesis, which was incubated at 16C for 2 hr in a thermocycler (heated lid option turned off). The double-stranded cDNA was then filter purified and added to a 4 hr in vitro transcription reaction. Last, the resulting cRNA was purified by glass filter and eluted in nuclease-free water for analysis by Agilent 2100 bioanalyzer and NanoDrop Spectrophotometer.


ArrayScript is Suitable for all RT Applications
Reverse transcriptases are also used in RT-PCR, cDNA library construction, and RLM-RACE. In most of these applications, synthesis of full-length cDNA is a critical parameter that affects final experimental results. For example, high yields of full-length cDNA result in the generation of cDNA libraries that more faithfully represent the cellular transcriptome. The
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Maximize Viral RNA Yield from Biological Fluid
2. Rapid Chromatography Optimization by pH Scouting Using the New BioLogic Maximizer Valve System, Rev A
3. Yeast Protein Production System Features High Yields and One-Step Purification
4. Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue
5. Synthesize High Yields of Biotinylated aRNA
6. Translate High Yields of Active Protein
7. Translate High Yields of Biologically Active Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ArrayScript Maximize Yields Full length cDNA

(Date:12/17/2014)... (PRWEB) December 17, 2014 Xeno ... Excellence following its most recent COLA inspection. Xeno ... COLA, a national healthcare accreditation organization. Accreditation is ... of quality in day-to-day operations, demonstrate continued accuracy ... a rigorous on-site laboratory survey. , ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... DNA2.0, the leading synthetic genomics company, announced today a significant ... interface, a customer-friendly site navigation, a database of published synthetic ... with a powerful resource for analyzing DNA and protein sequences. ... ...
... at the Canadian,Diabetes Association Congress, physicians will get ... phase 3b clinical study (LEAD(TM) 6) comparing,the investigational ... liraglutide, a human GLP-1 analog administered once daily ... (as,measured by HbA1c) than exenatide, a GLP-1 mimetic ...
... field called transformation optics may usher in a host ... ultra-powerful microscopes and computers by harnessing nanotechnology and "metamaterials." ... those in Einstein,s theory of general relativity, will be ... 17) in the journal Science . The article ...
Cached Biology Technology:DNA2.0 Launches New Website: Enhanced Design and Free Bioinformatics Tools Demonstrate DNA2.0's Customer Focus 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4New research field promises radical advances in optical technologies 2New research field promises radical advances in optical technologies 3New research field promises radical advances in optical technologies 4
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... mothers-to-be have a remarkable way to protect their unborn ... can cause miscarriage and reactivate the ovulatory cycle, pregnant ... blocking their smell. Researchers from the European Molecular Biology ... nature of this ability. A surge of the chemical ...
... Biology (ASBMB) has announced the recipients of its ... for their outstanding achievements and contributions to science. ... Experimental Biology 2009 Meeting, April 18-22, in New ... NIDDK, National Institutes of Health, will give the ...
... Neurological experts from across the U.S. and other ... Medical Center will discuss the latest findings in basic ... International Fragile X Conference, to be held July 23-27 ... diagnosed with Fragile X also will be attending the ...
Cached Biology News:Pregnant mice block out unwelcome admirers to protect their pups 2ASBMB taps 8 scientists for top awards 2ASBMB taps 8 scientists for top awards 3Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings 2